Production of experimental AIDS vaccine. Technician selecting recombinant virus colonies that will be used to infect insect cells to express the desired protein for VaxSyn, an experimental AIDS vaccine. VaxSyn is based on a genetically-engineered, recombinant form of the HIV protein gp160, which is a precursor to one of HIV's surface proteins. VaxSyn contains no attenuated infectious parts of HIV & therefore carries no risk of transmitting AIDS. The vaccine is being developed by MicroGeneSys and is undergoing trials as a treatment of HIV- positive patients & as a potential vaccine against HIV infection.